Primary biliary cholangitis (PBC) is a chronic progressive autoimmune disorder characterized by small non-purulent ...

"Highly pathogenic" cases of bird flu has been confirmed at two places in Lancashire.

AnaptysBio plans to advance rosnilimab for RA, with a program update expected in the first half of 2026. Read why ANAB stock ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report ...

Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long ...

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in ...

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...

The Phase 3 ADAPT SERON study met its primary endpoint (p-value=0.0068), demonstrating that AChR-Ab seronegative gMG patients treated with VYVGART achieved a statistically significant improvement in ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...

Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine ...